reboxetine

Antidepressant

4–5 mg twice daily; maximum 12 mg daily

Molecular weight :409.5 (as mesilate)

%Protein binding :97 (92% in elderly)

%Excreted unchanged in urine : 10

Volume of distribution (L/kg) :26–63 litres

half-life – normal/ESRD (hrs) :13/26

20 to 50 : Dose as in normal renal function

10 to 20 : 2 mg twice daily and adjust according to response

<10 : 2 mg twice daily and adjust according to response

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Unknown dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

Potentially hazardous interactions with other drugs

Antibacterials: avoid concomitant use with macrolides and linezolid

Antidepressants: risk of increased toxicity with concomitant use with MAOI’s; avoid concomitant use with fluvoxamine

Antifungals: avoid concomitant use with imidazoles and triazoles

Antimalarials: avoid concomitant use with artemether with lumefantrine

Ciclosporin: use with caution as high concentrations of reboxetine inhibit CYP3A4 and CYP2D6

Sibutramine: increased risk of CNS toxicity – avoid concomitant use

–

Oral

–

–.